Impact of Selenium on Methotrexate Induced Spermatotoxicity; A Comparative Study

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (283 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: potentialdiseasestudy istumorchronic liver
  Phrases that lowered it: psoriasiseffectsmokingdiseasesthe aim
• Sponsor's past termination rate: 0.5% (lowers risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 406 (raises risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Blinding: single (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 7.0% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 609 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 47236 (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 735805 (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: 70.8% (lowers risk) · Drug's FDA history
• Maximum age: 60 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pharmacological Treatment of a Rare Genetic Disease: N-acetylcysteine in Myopathy Associated Selenoprotein N-related Myopathy (SEPN1-RM) NCT02505087 · started 2015 · scored riskier than 7% of active trials terminated
• Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants NCT01497431 · started 2011 · scored riskier than 9% of active trials completed
• Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. NCT04080622 · started 2019 · scored riskier than 28% of active trials completed
• Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen NCT02097173 · started 2013 · scored riskier than 5% of active trials completed
• Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia NCT02373579 · started 2012 · scored riskier than 27% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.